A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: Hodgkin Lymphoma

In brief

The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)

Key facts

Study ID

NCT02572167

Run by

Seagen Inc.

People needed

93

Starts

2015-10-31

Expected to finish

2021-10-21

Last updated by the study team

2022-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin lymphoma
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You may not qualify if…

• Previously treated with brentuximab vedotin, immune-oncology agents, or received an allogeneic or autologous stem cell transplant
• Documented history of a cerebral vascular event
• History of another invasive malignancy that has not been in remission for at least 3 years
• History of progressive multifocal leukoencephalopathy (PML)

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• Stanford Cancer Center — Stanford, California, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute / Wayne State University — Detroit, Michigan, United States
• Mayo Clinic Minnesota — Rochester, Minnesota, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Memorial Sloan Kettering Cancer Center - Commack — Commack, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• James Cancer Hospital / Ohio State University — Columbus, Ohio, United States
• Charles A. Sammons Cancer Center / Baylor University Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.